Literature DB >> 18650145

Benign pancreatic hyperenzymemia or Gullo's syndrome.

L Gullo1, L Lucrezio, M Migliori, M Bassi, V Nesticò, P L Costa.   

Abstract

Benign pancreatic hyperenzymemia is a newly identified syndrome characterized by an abnormal increase in serum pancreatic enzymes in the absence of pancreatic disease. The hyperenzymemia can occur sporadically or in a familial form, and all of the pancreatic enzymes show elevations. Although the condition is persistent, the enzyme elevations fluctuate considerably, even temporarily returning to normal levels at times. In this review the main characteristics of this syndrome are described.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650145     DOI: 10.2478/v10039-008-0027-7

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  5 in total

1.  Benign pancreatic hyperenzymemia (Gullo syndrome), histamine intolerance, and carbohydrate malabsorption.

Authors:  Wolfgang J Schnedl; Dietmar Enko; Harald Mangge; Michael Schenk; Sonja Lackner; Sandra J Holasek
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

2.  Gullo's Syndrome: A Case Report.

Authors:  Prabhat Kumar; Anindya Ghosh; Vaibhav Tandon; Ratnakar Sahoo
Journal:  J Clin Diagn Res       Date:  2016-02-01

3.  Asymptomatic and persistent elevation of pancreatic enzymes in an ulcerative colitis patient.

Authors:  Elisa Liverani; Filippo Leonardi; Lucia Castellani; Carla Cardamone; Andrea Belluzzi
Journal:  Case Rep Gastrointest Med       Date:  2013-05-14

4.  Letter to the editor.

Authors:  Dianne Mawby; Jacqueline Whittemore; Kellie Fecteau
Journal:  J Vet Intern Med       Date:  2014 Nov-Dec       Impact factor: 3.333

5.  Increased variability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjects with type 2 diabetes.

Authors:  Jaret Malloy; Kate Gurney; Kevin Shan; Ping Yan; Steve Chen
Journal:  Diabetes Metab Syndr Obes       Date:  2012-12-17       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.